Alzheimer’s disease is the most common cause of dementia in elderly people and affects more than 25 million individuals worldwide. This number will nearly double in the next 20 years.
Only through scientific curiosity and courageous innovation progress can be achieved to find new drug targets and develop them to effective therapies.
AVERGEN is located at the Stevenage Bioscience Catalyst between London and Cambridge. AVERGEN has access to state-of-the art research laboratories.